EARLY HEARING DETECTION AND INTERVENTION VIRTUAL CONFERENCE
MARCH 2-5, 2021
(Virtually the same conference, without elevators, airplane tickets, or hotel room keys)
10/14/2017 | 8:40 AM - 9:45 AM | Precision medicine in hearing loss | East Ballroom at Shalala Student Services Building
Precision medicine in hearing loss
Background: Precision medicine proposes customized medical care based on a patient’s unique genome, biomarkers, environment, and behaviors. The authors review current and future applications of precision medicine in HL as they relate to the four core qualities of precision medicine (P4): Predictive, personalized, patient-centered, and participatory. The authors then introduce a strategy for effective incorporation of HL precision medicine into design of future research studies, electronic medical records, and clinical practice to improve diagnostics, prognostics, and, ultimately, individualized patient treatment. Finally, specific anticipated ethical and economic concerns in this growing era of genomics-based HL care are discussed.
Results: Translating HL discoveries made in the laboratory to individualized treatments for patients is leading to quicker results with improved patient outcomes. The field of HL continues to be revolutionized by improved genomics, leading to more precise HL diagnosis, prognosis, and treatment. With increasing genetic precision, prenatal selection against – or for – a trait like deafness is rapidly becoming a reality, with ethical implications that require further discussion.
Conclusion: By integrating precision medicine principles into translational hearing loss research and clinical practice, hearing specialists are poised to effectively treat the heterogeneous causes and manifestations of HL on an individualized basis.
- Recognize that with recent advances in genetic sequencing and data analysis, the field of hearing loss (HL) is ideally positioned to adopt the strategies of precision medicine.
- Describe strategies for translating HL research to individualized treatments for patients.
- Discuss obstacles and ethical concerns for future applications of precision medicine in HL.
Presentation:
This presentation has not yet been uploaded.
Handouts:
Handout is not Available
Transcripts:
CART transcripts are NOT YET available, but will be posted shortly after the conference
Presenters/Authors
Jason Rudman
(), University of Miami Department of Otolaryngology, jason.rudman@jhsmiami.org;
Jason Rudman, MD is an Otolaryngology-head and neck surgery resident at the University of Miami Miller School of Medicine, with an anticipated completion date of June 2019. He graduated Summa Cum Laude with a Bachelor's of Science in Chemical Engineering at the University of Florida, followed by earning an MD and being inducted into the AOA medical honors society at the University of Miami Miller School of Medicine.
ASHA DISCLOSURE:
Financial -
Nonfinancial -
Xue Liu
(), University of Miami Miller School of Medicine, xliu@med.miami.edu;
Xue Zhong Liu,. M.D., Ph.D., FACS., an internationally renowned surgeon-scientist, is the Leonard M. Miller Professor and Vice Chair of Otolaryngology and Professor of Human Genetics, Biochemistry and Pediatrics. Dr. Liu is also Vice Chair of Research in the Department of Otolaryngology at the University of Miami Miller School of Medicine. Dr. Liu is Director of the Director of the Center for Communication Sciences & Disorders. Dr. Liu is an active member of the American Academy of Otolaryngology Head and Neck Surgery, fellow of American College of Surgeons, American Rhinological Society, American Academy of Otolaryngic Allergy, Florida Society of Otolaryngology/Head & Neck Surgery, Greater Miami ENT Society, American Society of Human Genetics, the Association for Research in Otolaryngology (ARO), and President of American Chinese Genetic Association (ACGA) (2014-2016)
Dr. Liu graduated from the West China University of Medical Sciences in Chengdu, China. He completed a general surgery internship and otolaryngology residency at the University of Miami. He obtained his Ph.D in Human Genetics in the University of Manchester and Postdoctoral training in Molecular Genetics at MRC Mammalian Unit, Oxford, in England. He is fully licensed and board certified in Otolaryngology. He specializes in the treatment of hearing loss and ear diseases. He was selected by his peers as one of the “Best Doctors in America”.
Dr. Liu's research focuses are on novel disease gene targets and treatment in hearing loss. He has had a career long interest in genetic deafness and has made many significant contributions to our understanding of the identification of deafness genes and to molecular pathogenesis of deafness and deafness as well as and clinical diagnosis/management of deafness over the past decade. Dr. Liu is the author of more than 150 scientific papers in top journals and medical book chapters covering a wide range of topics in genetics, molecular biology, clinical diagnosis, and treatments in otolaryngology. His research activities on hearing loss have been well funded by the National Institute of Health (NIH). He is one of the top NIH funded Otolaryngologists. He has received national and international recognition for his clinical activities, teaching and research in the field of hearing loss. He has also been the guest speaker at numerous national and international otolaryngology meetings presenting his research accomplishment.
ASHA DISCLOSURE:
Financial -
Nonfinancial -